Yalçın, N.; Aktaş, S.; Uyar, S.; Koca, N.
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes. Life 2025, 15, 722.
https://doi.org/10.3390/life15050722
AMA Style
Yalçın N, Aktaş S, Uyar S, Koca N.
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes. Life. 2025; 15(5):722.
https://doi.org/10.3390/life15050722
Chicago/Turabian Style
Yalçın, Nazif, Selman Aktaş, Seyit Uyar, and Nizameddin Koca.
2025. "Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes" Life 15, no. 5: 722.
https://doi.org/10.3390/life15050722
APA Style
Yalçın, N., Aktaş, S., Uyar, S., & Koca, N.
(2025). Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes. Life, 15(5), 722.
https://doi.org/10.3390/life15050722